Document Type : Research articles


1 Department of Biostatistics, School of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran


Background: Blood cancer is a type of cancer that affects the blood cells derived from the bone marrow. Leukemia, lymphoma, and myeloma are the most common subtypes. Usually, bone marrow transplantation (BMT) is performed alongside curative treatments, such as chemotherapy and radiotherapy to transfuse healthy hematopoietic stem cells into a person after their own unhealthy bone marrow has been treated to kill invasive cells.
Objectives: The aim of this study was to compare the percentage of remission (cure rate) between different types of blood cancer.
Methods: In this retrospective cohort study, 458 patients who received BMT between 2007 and 2014 were analyzed. Patients were followed up until 2017 to determine whether they were still alive or had relapsed. The defective Marshall-Olkin Extended Weibull model was used with death being the event of interest.
Results:The study included 34 cases of acute lymphoblastic leukemia, 155 cases of multiple myeloma, 59 cases of acute myeloid leukemia, 156 cases of Hodgkins lymphoma, and 54 cases of non -Hodgkin 's lymphoma. The cure rate was highest in patients with Hodgkin 's lymphoma and multiple myeloma, while it was lowest in patients with acute lymphoblastic leukemia. in addition, age had an inverse effect on the cure rate for blood cancer (P=0.003), and relapse after BMT had a negative effect on the cure rate (P=0.003). In addition, relapse before transplantation had no effect, and body mass index was found to influence cure rate. A sensitivity analysis showed that the estimated cure rates increased slightly with decreasing cohort length.
Conclusion: Multiple myeloma and Hodgkin 's lymphoma had the highest cure rate, while acute lymphoblastic leukemia is barely curable. Obesity may increase the potential for cure and the experience of recurrence after BMT is associated with a lower cure rate.


  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. doi: 10.3322/caac.21660. [PubMed: 33538338].
  2. Dong Y, Shi O, Zeng Q, Lu X, Wang W, Li Y, et al. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp Hematol Oncol. 2020;9:14. doi: 10.1186/s40164-020-00170-6. [PubMed: 32577323].
  3. Maller RA, Zhou X. Survival Analysis with Long-Term Survivors. Wiley. 1997.
  4. Othus M, Barlogie B, LeBlanc ML, Crowley JJ. Cure models as a useful statistical tool for analyzing survival. Clin Cancer Res. 2012;18(14):3731-6. doi: 10.1158/1078-0432.CCR-11-2859. [PubMed: 22675175].
  5. Amico M, Van Keilegom I. Cure Models in Survival Analysis. Annu Rev Stat Its Appl. 2018;5(1):311–42. doi: 10.1146/annurev-statistics-031017-100101.
  6. Baghestani AR, Hosseini-Baharanchi FS. An improper form of Weibull distribution for competing risks analysis with Bayesian approach. J Appl Stat. 2019;46(13):2409–17. doi: 10.1080/02664763.2019.1597027.
  7. Martinez EZ, Achcar JA. A new straightforward defective distribution for survival analysis in the presence of a cure fraction. J Stat Theory Pract. 2018;12(4):688–703. doi: 10.1080/15598608.2018.1460885.
  8. Weir CB, Jan A. BMI Classification Percentile And Cut Off Points Treasure Island (FL). StatPearls Publishing. 2023. [PubMed: 31082114].
  9. Rocha R, Nadarajah S, Tomazella V, Louzada F. A new class of defective models based on the Marshall–Olkin family of distributions for cure rate modeling. Comput Stat Data Anal. 2017;107:48–63. doi: 10.1016/j.csda.2016.10.001.
  10. Lee ET, Wang JW. Statistical methods for survival data analysis. Wiley. 2003.
  11. Hosseini-Baharanchi FS, Baghestani AR, Bashash D, Bonakchi H, Farhangi H. Relapse, mortality, and the associated factors in children with acute lymphoblastic leukemia; a competing risks analysis. Int J Cancer Manag. 2021;14(5). doi: 10.5812/ijcm.105920.
  12. Baghestani AR, Moamer S, Pourhoseingholi MA, Maboudi AAK, Ghoreshi B, Zali MR. Demographic and Pathological Predictors of Colorectal Cancer Survival in Competing Risk Model, Using Generalized Weibull Distribution. Int J Cancer Manag. 2017;10(6). doi: 10.5812/ijcm.7352.
  13. Moamer S, Baghestani AR, Pourhoseingholi MA, Maboudi AAK, Shahsavari S, Zali MR, et al. Application of the parametric regression model with the four-parameter log-logistic distribution for determining of the effecting factors on the survival rate of colorectal cancer patients in the presence of competing risks. Iran Red Crescent Med J. 2017;19(6). doi: 10.5812/ircmj.55609.
  14. Navarro WH, Loberiza FR, Bajorunaite R, van Besien K, Vose JM, Lazarus HM, et al. Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2006;12(5):541-51. doi: 10.1016/j.bbmt.2005.12.033. [PubMed: 16635789].
  15. Paviglianiti A. A review on the impact of body mass index on outcomes in pediatric leukemia. J Blood Med. 2020;11:205-12. doi: 10.2147/JBM.S232655. [PubMed: 32607038].
  16. Reshef R, Hexner EO, Loren AW, Frey N V., Stadtmauer EA, Luger SM, et al. Early Donor Chimerism Levels Predict Relapse and Survival after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant. 2014;20(11):1758-66. doi: 10.1016/j.bbmt.2014.07.003. [PubMed: 25016197].
  17. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29(16):2230-9. doi: 10.1200/JCO.2010.33.7212. [PubMed: 21464398].
  18. Gupta V, Eapen M, Brazauskas R, Carreras J, Aljurf M, Gale RP, et al. Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica. 2010;95(12):2119-25. doi: 10.3324/haematol.2010.026682. [PubMed: 20851870].
  19. Popplewell LL, Forman SJ. Is there an upper age limit for bone marrow transplantation? Bone Marrow Transplant. 2002;29(4):277-84. doi: 10.1038/sj.bmt.1703382. [PubMed: 11896423].
  20. Gonçalves TL, Benvegnù DM, Bonfanti G. Specific factors influence the success of autologous and allogeneic hematopoietic stem cell transplantation. Oxid Med Cell Longev. 2009;2(2):82-7. doi: 10.4161/oxim.2.2.8355. [PubMed: 20357929].
  21. Kim HT, Zhang MJ, Woolfrey AE, Martin AS, Chen J, Saber W, et al. Donor and recipient sex in allogeneic stem cell transplantation: What really matters. Haematologica. 2016;101(10):1260-66. doi: 10.3324/haematol.2016.147645. [PubMed: 27354023].
  22. Ditschkowski M, Beelen DW, Trenschel R, Koldehoff M, Elmaagacli AH. Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant. 2004;34(9):807-13. doi: 10.1038/sj.bmt.1704657. [PubMed: 15354205].
  23. Xenocostas A, Yee A, Wong CJ, Sutton DMC, Lipton JH, Kiss TL, et al. RBC transfusion requirements after allogeneic marrow transplantation: Impact of the before-transplant Hb level on transfusion and early survival. Transfusion. 2003;43(3):373-82. doi: 10.1046/j.1537-2995.2003.00339.x. [PubMed: 12675724].
  24. Stedman MR, Feuer EJ, Mariotto AB. Current estimates of the cure fraction: A feasibility study of statistical cure for breast and colorectal cancer. J Natl Cancer Inst Monogr. 2014;2014(49):244-54. doi: 10.1093/jncimonographs/lgu015. [PubMed: 25417238].